U.S. Approves Second Coronavirus Vaccine

U.S. Approves Second Coronavirus Vaccine

The U.S. Food and Drug Administration (FDA) has approved a second coronavirus vaccine for use in the country.

It is a product of the American company Moderna. It is noted that the body of available data provides clear evidence that the vaccine can be effective in preventing COVID-19. “The data also show that the known and potential benefits outweigh the known and potential risks,” the FDA noted, specifying that the drug can be used in patients over the age of 18.

The regulator also pointed out that the most common side effects, which typically lasted several days after vaccination, were pain at the injection site, fatigue, headache, muscle pain, chills, joint pain, enlarged lymph nodes in the same arm as the injection, nausea and vomiting, and fever. More people experienced these side effects after the second dose than after the first injection.

On December 18, it was reported that Moderna destroyed approximately 400,000 doses of its coronavirus vaccine. The company was forced to reject the batch due to filtration problems encountered at a late stage of production. The drug had not yet been poured into vials. However, Moderna believes that the incident will not affect plans to produce 20 million doses by the end of the month.

On Dec. 13, guidelines from the federal Centers for Disease Control and Prevention (CDC) approved BioNTech and Pfizer’s emergency vaccine for use in the United States. The first person to receive the BioNTech and Pfizer vaccine in the U.S. was New York City nurse Sandra Lindsay, who has been working with COVID-19 patients for the past ten months.

To date, there are several vaccines against COVID-19 in the world. Thus, two vaccines are registered in Russia: Sputnik V and EpiVacCorona. On December 5, vaccination against coronavirus with Sputnik V started in Moscow. In the U.S. a COVID-19 vaccine produced by Pfizer and BioNTech has been registered, and a vaccine developed by Moderna is next in line. Also, the British pharmaceutical company AstraZeneca announced the beginning of clinical trials of its vaccine combination AZD1222.